Skip to content

BONE BIOLOGICS CORPORATION: 10-Q filed 2021-04-15

What BONE BIOLOGICS CORPORATION reported in its quarterly report filed 2021-04-15 (fiscal Q3 2020): 23 published measures, 64 facts as tagged in accession 0001493152-21-008878.

This filing

Form
10-Q (quarterly report)
Filed
2021-04-15
Fiscal period
fiscal Q3 2020
Accession
0001493152-21-008878 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BONE BIOLOGICS CORPORATION filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-3013,241,060USD
At 2019-12-3111,898,447USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-13,238,599USD
At 2020-06-30-12,844,550USD
At 2020-03-31-12,464,520USD
At 2019-12-31-11,867,620USD
At 2019-09-30-11,382,137USD
At 2019-06-30-10,855,108USD
At 2019-03-31-9,971,690USD
At 2018-12-31-8,598,175USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-302,461USD
At 2019-12-3124,145USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-394,049USD92
2020-01-01 to 2020-09-30-1,370,979USD274
2020-04-01 to 2020-06-30-380,030USD91
2020-01-01 to 2020-03-31-596,900USD91
2019-07-01 to 2019-09-30-561,419USD92
2019-01-01 to 2019-09-30-2,893,664USD273
2019-04-01 to 2019-06-30-925,552USD91
2019-01-01 to 2019-03-31-1,406,693USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-301,240USD274
2019-01-01 to 2019-09-30-2,953,540USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,070,000,000USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-30279,556USD274
2019-01-01 to 2019-09-302,200,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-68,411,211USD
At 2019-12-31-67,040,232USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,600USD274
2019-07-01 to 2019-09-3039USD92
2019-01-01 to 2019-09-301,639USD273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-09-3046,566USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-145,823USD92
2020-01-01 to 2020-09-30-618,582USD274
2019-07-01 to 2019-09-30-301,310USD92
2019-01-01 to 2019-09-30-2,169,805USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-302,461USD
At 2019-12-3130,827USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-3013,241,060USD
At 2019-12-31578,447USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-30399,657USD
At 2019-12-3142,879USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-30145,823USD92
2020-01-01 to 2020-09-30618,582USD274
2019-07-01 to 2019-09-30301,310USD92
2019-01-01 to 2019-09-302,169,805USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-30142,877USD92
2020-01-01 to 2020-09-30318,978USD274
2019-07-01 to 2019-09-3044,942USD92
2019-01-01 to 2019-09-301,026,840USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3030,682,590shares
At 2019-12-3130,682,590shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3055,141,930USD
At 2019-12-3155,141,930USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-394,049USD92
2020-01-01 to 2020-09-30-1,369,379USD274
2019-07-01 to 2019-09-30-561,380USD92
2019-01-01 to 2019-09-30-2,892,025USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-302,946USD92
2020-01-01 to 2020-09-30299,604USD274
2019-07-01 to 2019-09-30256,368USD92
2019-01-01 to 2019-09-301,142,965USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-01-01 to 2019-09-3050USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-01-01 to 2019-09-30717,965USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2019-01-01 to 2019-09-301,639USD273

Inspect the source

Entity
BONE BIOLOGICS CORPORATION / CIK 0001419554
Captured
2026-09-20T08:02:52.100Z
SEC response SHA-256
7c2684db7febb4ea6b03577e138dc91ed20e12534f1d96c178894d4b68a7b815

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001419554.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))